Aclaris Therapeutics Inc. (ACRS): Debt to Book Capitalization Ratio
Aclaris Therapeutics (ACRS) management is pragmatically optimizing its research portfolio, focusing on therapies for dermatological and immune pathologies. This price chart reflects a market trend for the asset with a value of 0.01. High patent barriers and strict FDA oversight limit access to this niche. Meanwhile, investors maintain cautious optimism, awaiting new trial data from this persistent developer.
&width=1200&height=400&colorIndex=0&v=mvt4kixj.9g-7avve2o&start=20220704&end=20261029&filename=GURU_Markets_-_ACRS_-_Aclaris-Therapeutics_-_Debt-to-Net-Assets-Ratio "ACRS: Aclaris Therapeutics Debt to Book Capitalization Ratio 07/04/2022 - 10/29/2026 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for Aclaris Therapeutics Inc. (ACRS)
- current price and projected stock value:
- stock exchange capitalization data:
- book value of equity indicators:
- debt and solvency information:
Total Debt to Equity Ratio Aclaris Therapeutics|ACRS - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Aclaris|ACRS - Company Total Debt Obligations|Debt to Book Capitalization Ratio Aclaris Therapeutics, Inc|ACRS - Company Long-Term Liabilities|Company Short-Term Debt Aclaris Therapeutics|Quick Liquidity Indicator aclaristx.com
- business earnings and investment ratios data:
Comprehensive company analysis:ACRS (Aclaris Therapeutics)
This indicator compares total liabilities to total equity, measuring the degree of financial leverage and the balance sheet's dependence on borrowed funds. Amid workforce reductions and the search for buyers for Aclaris Therapeutics (ACRS) assets, the company's debt-to-book capitalization ratio reflects liquidity risk during the revision of its business development strategy.
Competitors of Aclaris Therapeutics (ACRS)
Debts to Book Capitalization ARGX (argenx SE)|Debts to Book Capitalization biontech.de BNTX|ABVX - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio ADMA (ADMA Biologics Inc)|Protagonist Therapeutics Inc (PTGX) - Debt to Book Capitalization Ratio|Debt to Book Value Immunovant Therapeutics|KNSA (Kiniksa Pharmaceuticals) - Debts to Book Capitalization|Debts to Book Capitalization grifols.com|Debt to Book Value ADPT (Adaptive Biotechnologies Corporation)|CLDX (Celldex Therapeutics Inc) - Debt to Net Assets Ratio|Debts to Book Capitalization AUPH (Aurinia Pharma)|Debts to Net Assets BioCryst Corp (BCRX)|VERA - Debt to Book Capitalization Ratio|dianthustx.com (DNTH) - Debt to Book Value|Pharvaris (PHVS) - Debt to Book Capitalization Ratio|Debt to Book Value AbCellera Bio|Debt to Book Value TRML|Debts to Book Capitalization Precigen Corp|Debt to Book Capitalization Ratio Pharming Group N.V. (PHAR)|nektar.com - Debt to Book Value Ratio|Debts to Book Capitalization UPB (Upstream Bio)|Zenas Bio (ZBIO) - Debts to Book Value|Immunome Corp - Debts to Book Capitalization|GOSS - Debts to Book Capitalization|KALV: Debts to Book Capitalization|Debt to Book Value septerna.com|Debt to Book Capitalization Ratio Pieris Pharmaceuticals, Inc.|Debt to Book Capitalization Ratio SVRA|Debts to Book Capitalization RIGL|Debts to Book Capitalization AnaptysBio Inc. (ANAB)|Debt to Book Capitalization Ratio Astria Therapeutics ATXS|Debt to Net Assets Ratio ENGN|RAPT Therapeutics, Inc. - Debts to Book Capitalization|Debts to Net Assets Aerovate Therapeutics Inc JBIO|Kyverna (KYTX) - Debt to Book Capitalization Ratio|TLSA - Debts to Net Assets|Debt to Book Value CABA|VTYX: Debt to Net Assets Ratio|Debt to Book Value THTX (Theratechnologies)|Debt to Book Capital AVTX|Debts to Book Capitalization ELDN (Eledon)|Debt to Net Assets Ratio AGEN|Climb Bio Inc - Debts to Book Capitalization|Debts to Book Value Zura Bio Ltd|aTyr Pharma (ATYR) - Debt to Book Capitalization Ratio|Adagene Inc. - Debt to Net Assets Ratio|IMA (ImageneBio) - Debts to Book Capitalization|Debts to Book Capitalization Shattuck Therapeutics|Debt to Book Capitalization Ratio Equillium, Inc. (EQ)|CNTB: Debts to Book Capitalization Ratio|Debts to Book Capitalization IMUX (Immunic)|Atara Biotherapeutics, Inc. (ATRA) - Debts to Book Value|IFRX: Debt to Book Value|XFOR - Debts to Book Capitalization|ACET (adicetbio.com) - Debt to Book Value|CELU: Debt to Book Capital|INMB (INmune Bio) - Debts to Book Capitalization|Barinthus Biotherapeutics PLC (BRNS) - Debts to Net Assets|Debts to Book Capitalization KZR|Debt to Book Value SAB Biotherapeutics Inc SABS|Debt to Book Capitalization Ratio Akari Therapeutics AKTX|Debts to Net Assets Enlivex Therapeutics Ltd (ENLV)|Q32 Bio Corp - Debts to Book Capitalization|GOVX - Debts to Book Capitalization|EDSA: Debts to Book Capitalization|Debt to Book Value iBio Corporation|Debt to Book Capitalization Ratio Carisma Therapeutics Inc|XTLB: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio Bolt Biotherapeutics (BOLT)|Debts to Net Assets hcwbiologics.com|Debt to Book Capitalization Ratio Aptevo Therapeutics Inc. APVO|AIM (AIM ImmunoTech, Inc.) - Debts to Book Capitalization Ratio|Aditxt Corp - Debts to Book Capitalization|Debt to Net Assets Ratio GRI (gribio.com)|XRTX: Debts to Book Capitalization|Vyome Holdings Inc. (HIND) - Debts to Book Capitalization|Debt to Book Capitalization Ratio Revelation Bio|INDP: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio Scinai Immunotherapeutics (SCNI)|Debt to Book Value calcimedica.com CALI|Debts to Book Capitalization AFMD (Affimed N.V.)|Debts to Book Capitalization Allakos Inc ALLK|HOOK: Debt to Book Value|Debt to Net Assets Ratio IGMS (IGM Biosciences, Inc.)|ITOS: Debts to Book Capitalization|OCEA - Debts to Net Assets|Debt to Book Capitalization Ratio TC BioPharm|Debt to Book Value Third Harmonic Bio Inc. (THRD)